

ARCA biopharma, Inc.
Form 10-Q
August 13, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2013

OR

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO

Commission File Number 000-22873

ARCA BIOPHARMA, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of

36-3855489
(I.R.S. Employer

Edgar Filing: ARCA biopharma, Inc. - Form 10-Q

Incorporation or Organization)	Identification Number)
8001 Arista Place, Suite 430 Broomfield, CO	80021
(Address of Principal Executive Offices)	(Zip Code)
(720) 940-2200	

(Registrant's Telephone Number, including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer
Non-accelerated filer (Do not check if smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Number of Shares Outstanding
Common Stock \$0.001 par value	On August 9, 2013: 10,950,762

	PAGE
Part I Financial Information	
<u>Item 1. Consolidated Financial Statements (unaudited)</u>	
	3
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	
	17
<u>Item 3. Quantitative and Qualitative Disclosures about Market Risk</u>	
	22
<u>Item 4. Controls and Procedures</u>	
	22
Part II Other Information	
<u>Item 1. Legal Proceedings</u>	
	22
<u>Item 1A. Risk Factors</u>	
	22
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	
	42
<u>Item 3. Defaults Upon Senior Securities</u>	
	42
<u>Item 4. Mine Safety Disclosures</u>	
	42
<u>Item 5. Other Information</u>	
	42
<u>Item 6. Exhibits</u>	43
<u>Signature</u>	44

PART I. FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

ARCA BIOPHARMA, INC.

(a development stage enterprise)

CONSOLIDATED BALANCE SHEETS

(Unaudited)

	June 30, 2013	December 31, 2012
	(in thousands, except share and per share amounts)	
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 20,374	\$ 2,920
Other current assets	284	125
Total current assets	20,658	3,045
Property and equipment, net	21	23
Other assets	104	144
Total assets	\$ 20,783	\$ 3,212
LIABILITIES AND STOCKHOLDERS EQUITY		
Current liabilities:		
Accounts payable	\$ 387	\$ 65
Accrued compensation and employee benefits	103	103
Accrued expenses and other liabilities	257	121
Deferred rent, current portion	3	16
Total current liabilities	750	305
Total liabilities	\$ 750	\$ 305
Commitments and contingencies		
Stockholders' equity:		
Series A convertible preferred stock, \$0.001 par value; 135,000 shares authorized; 55,894 shares issued and outstanding at June 30, 2013; no shares authorized, issued and outstanding at December 31, 2012		
Common stock, \$0.001 par value; 100 million shares authorized; 10,096,162 shares issued and outstanding at June 30, 2013; 2,660,315 shares issued and outstanding at December 31, 2012.	10	3
Additional paid-in capital	90,287	70,898

Edgar Filing: ARCA biopharma, Inc. - Form 10-Q

Deficit accumulated during the development stage	(70,264)	(67,994)
Total stockholders' equity	20,033	2,907
Total liabilities and stockholders' equity	\$ 20,783	\$ 3,212

See accompanying notes to consolidated financial statements

ARCA BIOPHARMA, INC.

(a development stage enterprise)

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,		Period from
	2013	2012	2013	2012	December 17, 2001 (date of inception) to June 30, 2013
					(in thousands, except share and per share amounts)
Costs and expenses:					
Research and development	\$ 246	\$ 322	\$ 427		